Order on LG&E/KU Rate Adjustment Motions

The Kentucky Public Service Commission issued an order addressing motions for corrections and clarification filed by Louisville Gas and Electric Company (LG&E) and Kentucky Utilities Company (KU) regarding a prior rate increase approval. The order also addresses multiple petitions for rehearing and reconsideration filed by various parties, including LG&E/KU, Joint Intervenors, and the Broadband and Cable Association.

Kentucky American Water Company Seeks $100M Debt Authority

The Kentucky Public Service Commission approved Kentucky American Water Company's application to issue indebtedness in an aggregate principal amount not to exceed $100,000,000 through December 31, 2027. The authorization covers four separate long-term debt financing events planned between May 2026 and September 2027, with proceeds to refinance short-term debt used for construction expenditures and acquisition activities. The Commission found the request satisfies the lawful object and public service standards under KRS 278.300.

Mountain Water District Rate Case Decision Without Hearing

The Kentucky Public Service Commission issued an order granting in part Mountain Water District's motion to submit Case No. 2025-00327 for a decision without a hearing. The Commission granted the request to decide the rate case on the existing record but denied the request to close the record as of March 31, 2026. The record will remain open until further Order to allow Commission Staff to issue additional information requests and for Mountain Water District to submit a supplemental rate case expense report.

SSA and VA New Matching Program Notice Re-establishment

The Social Security Administration (SSA) has issued a notice announcing the re-establishment of a matching program with the Department of Veterans Affairs (VA). This program will allow VA to provide SSA with compensation and pension payment data to administer SSI, SVB, Medicare Savings Program, and Medicare Part D subsidy.

Proposed Rule Change to NYSE American Options Fee Schedule

NYSE American LLC has filed a proposed rule change with the SEC to modify its Options Fee Schedule. The changes affect fees and rebates for Non-Customers and Floor Brokers, including extending a surcharge to manual orders and establishing a new rebate for Floor Broker orders trading with Floor Market Maker orders. The proposed effective date is March 10, 2026.

NYSE American Proposes Rule Change for Options Fee Schedule

NYSE American LLC has filed a proposed rule change with the SEC to amend its Options Fee Schedule. The change will adopt fees for trading options overlying the MSCI EAFE Index and the MSCI Emerging Markets Index, effective March 16, 2026.

NYSE Proposal to Amend Options Series Program for Monday/Wednesday Expirations

The NYSE has proposed amendments to its options series program concerning Monday and Wednesday expirations. This filing initiates a public comment period, allowing interested parties to submit feedback on the proposed changes to the options market structure.

NYSE American Proposal to Amend Rule 7.18E Regarding Halts

NYSE American has proposed an amendment to Rule 7.18E concerning trading halts. The proposal aims to enhance the clarity and efficiency of the halt process by introducing new provisions for the dissemination of information and the duration of trading pauses. Public comments are being accepted on this proposal.

NYSE Arca Modifies Options Fee Schedule for Non-Customers and Floor Brokers

NYSE Arca has filed a proposed rule change with the SEC to modify its Options Fee Schedule. The changes include extending a surcharge to manual complex orders and establishing a rebate for floor broker orders that trade with market maker orders. The filing is open for public comment.

NYSE Arca Options Fee Schedule Rule Change - March 2026

NYSE Arca, Inc. has filed a proposed rule change to modify its Options Fee Schedule. The change seeks to waive the combined cap on Submitting Broker credits and Floor Broker rebates for March 2026, to prevent firms from redirecting order flow due to reaching the cap. The SEC is soliciting comments on this proposal.

NYSE ARCA proposal to amend options series program

NYSE has proposed amendments to its options series program under NYSE Arca Rule 19b-4. The proposed rule change aims to enhance the program's efficiency and flexibility. Public comments are being accepted on this proposal.

DOT Announces $488.6M Investment in Ports to Restore Maritime Dominance

The U.S. Department of Transportation's Maritime Administration (MARAD) announced $488,628,000 in funding through the Port Infrastructure Development Program (PIDP) to modernize ports, strengthen supply chains, and restore American maritime dominance. The funding will support projects improving port operations, streamlining supply chains, and modernizing infrastructure.

DOT Announces Nearly $1 Billion for Road Safety Infrastructure

The U.S. Department of Transportation announced the availability of nearly $1 billion in funding through the Safe Streets & Roads for All (SS4A) grant program. This funding aims to upgrade crucial safety infrastructure, improve emergency response, expand truck parking, modernize rail crossings, and enhance family-focused infrastructure across American roads.

DOT Invests $13.3 Million in Marine Highway Infrastructure Projects

The U.S. Department of Transportation's Maritime Administration (MARAD) announced an investment of over $13 million in 11 marine highway projects across seven states. This funding aims to support public and private partners in developing supply chains on marine highway routes, enhancing national freight capacity and easing congestion.

Thomas R. Clark Sentencing Motion Denied

The Delaware Superior Court denied Thomas R. Clark's motion for correction of an illegal sentence. Clark pleaded guilty to firearm offenses and was sentenced on October 1, 2024. The court found his motion lacked merit, as his sentence was negotiated and agreed upon as part of a plea agreement.

JUUL Labs Motion to Dismiss Granted in Part, Denied in Part

The Delaware Superior Court granted in part and denied in part JUUL Labs, Inc.'s motion to dismiss twelve consolidated cases involving 1,005 plaintiffs. The court found that the Delaware cases were the first-filed actions and denied JUUL's forum non conveniens argument, while also addressing issues of misjoinder.

Scruggs v. Just Food for Dogs - Appeal of Industrial Accident Board Decision

The Delaware Superior Court affirmed the Industrial Accident Board's decision to reduce Joyce Scruggs' partial disability compensation and deny coverage for her proposed surgery. The court found substantial evidence supported the Board's findings regarding the necessity of the surgery and the reduction in benefits.

Porter v. State of Delaware - Conflict of Interest Claim

The Delaware Superior Court issued findings of fact and conclusions of law on remand regarding Christopher Porter's conflict of interest claim. The court addressed whether Mr. Porter's defense counsel maintained a conflict of interest and if he provided informed consent to waive it.

Executive Order Banning Insider Betting by State Officials

California Governor Gavin Newsom issued an executive order strengthening bans on state officials using non-public information for personal profit, specifically targeting prediction markets. The order extends prohibitions to appointees and their associates, aiming to prevent corruption fueled by insider knowledge, particularly in light of federal examples.

Guangdong Cell Biotechnology Ltd v. Sudhof - Motion to Dismiss

The U.S. District Court for the Northern District of California has filed a motion to dismiss in the case of Guangdong Cell Biotechnology Ltd v. Sudhof. The motion was filed on March 28, 2026, with a hearing scheduled for May 12, 2026.

Ulloa II v. Securitas Security Services USA, Inc. - Labor Case

The U.S. District Court for the Northern District of California has filed a new labor case, Ulloa II v. Securitas Security Services USA, Inc., on April 12, 2023. Recent filings include motions for leave to file an amended complaint and to certify a class, with a hearing set for July 2026.

Fuchs v. City of Berkeley et al - Civil Rights Case

The U.S. District Court for the Northern District of California has filed a new civil rights case, Fuchs v. City of Berkeley et al. The case was filed on March 9, 2026, under Federal Question jurisdiction. A recent filing includes a motion for an extension of time to file a response.

Apple Inc. v. Shi et al - Case Status Report Filing

The U.S. District Court for the Northern District of California has received a joint status report filing in the case of Apple Inc. v. Shi et al. This filing, dated March 28, 2026, is part of ongoing civil litigation proceedings.

Zhang v. USCIS - Voluntary Dismissal Filed

The U.S. District Court for the Northern District of California has recorded a voluntary dismissal in the case of Zhang v. USCIS. The dismissal was filed by the plaintiff, Zhenyu Zhang, on March 28, 2026, concluding the civil action.

FDA Complaint Document Posted

The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. This document is available for public review and comment, with a specific deadline for submissions.

FDA Complaint Document Details

The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document is available for review on the regulations.gov portal, with a specific detail date of March 27, 2026. No further details on the nature of the complaint or its implications are provided in the initial posting.

FDA Complaint Filed and Closed for Comments

The Food and Drug Administration (FDA) has filed a complaint and opened it for public comment. The complaint is related to the Center for Tobacco Products (CTP) and has a filing date of March 27, 2026.

Preeclampsia Risk and IVF Cycles Guidance

The Food and Drug Administration (FDA) has issued new guidance regarding the risk of preeclampsia associated with in vitro fertilization (IVF) cycles. This guidance aims to inform healthcare providers and patients about potential risks and management strategies.

FDA Complaint Document

The Food and Drug Administration (FDA) has posted a complaint document to the Federal Docket Management System. The document, authored by CTP, is available for review and download via the provided links.

FDA Complaint Filed for Public Comment

The Food and Drug Administration (FDA) has opened a public comment period for a filed complaint related to its regulations. The complaint, authored by CTP, is available for review and download on regulations.gov. This action initiates a consultation period for interested parties to provide feedback.

FDA Complaint Docket FDA-2026-H-3040

The Food and Drug Administration (FDA) has opened a new complaint docket, FDA-2026-H-3040, related to a complaint filed by CTP. No documents are currently available for viewing or download within this docket.

FDA Background Material for Docket FDA-2026-P-3242

The Food and Drug Administration (FDA) has posted background material related to docket FDA-2026-P-3242. This material is available for public review and does not impose new regulatory requirements.

FDA Complaint Document Posted for Comments

The Food and Drug Administration (FDA) has posted a complaint document for public comment, with the comment period closing on March 27, 2026. The document is related to a complaint filed by CTP.

Citizen Petition from Charlene Peters

The Food and Drug Administration (FDA) has received a citizen petition from Charlene Peters. The petition is currently available for review, with a redacted version provided for public access.

FDA Supporting Material for Proposed Rule

The Food and Drug Administration (FDA) has posted supporting material for a proposed rule on March 27, 2026. This material is associated with docket number FDA-2026-P-3242. The posting provides additional context and data related to the proposed regulatory action.

FDA Complaint Document

The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document, authored by the Center for Tobacco Products (CTP), is available for review and download via the regulations.gov portal.

FDA Acknowledgement Letter to Charlene Peters

The Food and Drug Administration (FDA) has issued an acknowledgement letter to Charlene Peters regarding a submission. The letter, authored by CDER, confirms receipt of the document. No specific details about the submission's content or regulatory implications are provided.

FDA Complaint Document

The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document, authored by CTP, is available for review on Regulations.gov. No specific compliance actions or deadlines are indicated.

Appco Pharma LLC Suitability Petition

The Food and Drug Administration (FDA) has received a suitability petition from Appco Pharma LLC. The petition is related to drug manufacturing and regulatory filings.

FDA Complaint Filed and Closed for Comments

The Food and Drug Administration (FDA) has filed a complaint and opened it for public comment. The complaint, filed on March 27, 2026, is available for review and submission of feedback through the Regs.gov portal.

FDA Document on Uterine Lavage and Live Births

The Food and Drug Administration (FDA) has issued a document concerning uterine lavage and its relation to live births. This notice provides information on the topic, likely for public awareness or to inform stakeholders in the healthcare and pharmaceutical sectors.

Mifepristone Clinical Indications Systematic Review Document

The Food and Drug Administration has issued a systematic review document regarding the clinical indications for mifepristone. This document outlines the FDA's review process and findings related to the drug's approved uses.

FDA Acknowledgement Letter to Steranco Healthcare Pvt. Ltd.

The Food and Drug Administration (FDA) has issued an acknowledgement letter to Steranco Healthcare Pvt. Ltd. The letter confirms receipt of documentation related to a submission. No specific details regarding the nature of the submission or any required actions are provided in the available information.

FDA Complaint Filed and Closed for Comments

The Food and Drug Administration (FDA) has filed a complaint and opened it for public comment. The complaint, filed on March 27, 2026, is available for review and submission of feedback.

FDA Final Response

The Food and Drug Administration (FDA) has posted a final response related to docket FDA-2022-P-2644-0046. The document, authored by CDRH, is available via the provided URL and download link.

FDA Complaint Document Closed for Comments

The Food and Drug Administration (FDA) has closed a complaint document for public comments. The document, authored by CTP, is available for download via a link on regulations.gov. No specific details about the complaint's content or its regulatory impact are provided.

PGT-A Using Human In Vivo - Part 1 & 2

FDA's Center for Drug Evaluation and Research (CDER) received a submission titled 'PGT-A using human in vivo - Part 1 & 2' filed on regulations.gov under docket FDA-2026-P-3169-0007. The landing page indicates no documents are currently available to view or download, though two PDF attachments are listed. The submission relates to preimplantation genetic testing for aneuploidy (PGT-A) using human in vivo methodology.

Giftify, Inc. - Notice of Delisting or Failure to Satisfy Listing Rule

Giftify, Inc. received a notice from Nasdaq indicating its common stock is non-compliant with the minimum bid price requirement of $1 per share. The company has 180 days to regain compliance, potentially through a reverse stock split, or face delisting.

Immersion Corp - Notice of Delisting or Failure to Satisfy Continued Listing Rule

Immersion Corporation received an additional delinquency notice from Nasdaq for failing to file its Quarterly Reports on Form 10-Q for the fiscal quarters ended January 31, 2026, October 31, 2025, and July 31, 2025. The company has requested a hearing to seek additional time to comply with Nasdaq Listing Rules.

BiomX Inc. - Notice of Delisting or Failure to Satisfy Continued Listing Rule

BiomX Inc. received a notice from NYSE American for failing to meet continued listing standards related to minimum stockholders' equity. The company must submit a plan by April 24, 2026, to regain compliance by September 25, 2027.